Elixinol Global Stock Beta
| ELLXF Stock | USD 0.01 0.01 205.56% |
Fundamental analysis of Elixinol Global allows traders to better anticipate movements in Elixinol Global's stock price by examining its financial health and performance throughout various phases of its business cycle.
Elixinol |
Elixinol Global Company Beta Analysis
Elixinol Global's Beta is one of the most important measures of equity market volatility. Beta can be thought of as asset elasticity or sensitivity to market. In other words, it is a number that shows the relationship of an equity instrument to the financial market in which this instrument is traded. For example, if Beta of equity is 2, it is expected to significantly outperform market when the market is going up and significantly underperform when the market is going down. Similarly, Beta of 1 indicates that an asset and market will generate similar returns over time.
Current Elixinol Global Beta | 1.71 |
Most of Elixinol Global's fundamental indicators, such as Beta, are part of a valuation analysis module that helps investors searching for stocks that are currently trading at higher or lower prices than their real value. If the real value is higher than the market price, Elixinol Global is considered to be undervalued, and we provide a buy recommendation. Otherwise, we render a sell signal.
In a nutshell, Beta is a measure of individual stock risk relative to the overall volatility of the stock market. and is calculated based on very sound finance theory - Capital Assets Pricing Model (CAPM).However, since Beta is calculated based on historical price movements it may not predict how a firm's stock is going to perform in the future.
| Competition |
In accordance with the recently published financial statements, Elixinol Global has a Beta of 1.7067. This is 98.45% higher than that of the Healthcare sector and significantly higher than that of the Drug Manufacturers—Specialty & Generic industry. The beta for all United States stocks is notably lower than that of the firm.
Elixinol Beta Peer Comparison
Stock peer comparison is one of the most widely used and accepted methods of equity analyses. It analyses Elixinol Global's direct or indirect competition against its Beta to detect undervalued stocks with similar characteristics or determine the pink sheets which would be a good addition to a portfolio. Peer analysis of Elixinol Global could also be used in its relative valuation, which is a method of valuing Elixinol Global by comparing valuation metrics of similar companies.Elixinol Global is currently under evaluation in beta category among its peers.
As the market goes up, the company is expected to outperform it. However, if the market returns are negative, Elixinol Global will likely underperform.
Elixinol Fundamentals
| Return On Equity | -0.71 | |||
| Return On Asset | -0.33 | |||
| Profit Margin | (1.72) % | |||
| Operating Margin | (1.63) % | |||
| Current Valuation | 2.06 M | |||
| Shares Outstanding | 316.27 M | |||
| Shares Owned By Insiders | 15.67 % | |||
| Shares Owned By Institutions | 4.83 % | |||
| Price To Book | 0.72 X | |||
| Price To Sales | 0.59 X | |||
| Revenue | 14.13 M | |||
| Gross Profit | 4.9 M | |||
| EBITDA | (24.15 M) | |||
| Net Income | (17.02 M) | |||
| Cash And Equivalents | 6.93 M | |||
| Cash Per Share | 0.02 X | |||
| Total Debt | 250 K | |||
| Debt To Equity | 0.17 % | |||
| Current Ratio | 3.58 X | |||
| Book Value Per Share | 0.04 X | |||
| Cash Flow From Operations | (14.07 M) | |||
| Earnings Per Share | (0.04) X | |||
| Number Of Employees | 17 | |||
| Beta | 1.71 | |||
| Market Capitalization | 6.5 M | |||
| Total Asset | 25.33 M | |||
| Z Score | 15.0 | |||
| Net Asset | 25.33 M |
About Elixinol Global Fundamental Analysis
The Macroaxis Fundamental Analysis modules help investors analyze Elixinol Global's financials across various querterly and yearly statements, indicators and fundamental ratios. We help investors to determine the real value of Elixinol Global using virtually all public information available. We use both quantitative as well as qualitative analysis to arrive at the intrinsic value of Elixinol Global based on its fundamental data. In general, a quantitative approach, as applied to this company, focuses on analyzing financial statements comparatively, whereas a qaualitative method uses data that is important to a company's growth but cannot be measured and presented in a numerical way.
Please read more on our fundamental analysis page.
Currently Active Assets on Macroaxis
| VOO | Vanguard SP 500 | |
| XLK | Technology Select Sector | |
| XLV | Health Care Select | |
| QQQ | Invesco QQQ Trust | |
| XLC | Communication Services Select |
Other Information on Investing in Elixinol Pink Sheet
Elixinol Global financial ratios help investors to determine whether Elixinol Pink Sheet is cheap or expensive when compared to a particular measure, such as profits or enterprise value. In other words, they help investors to determine the cost of investment in Elixinol with respect to the benefits of owning Elixinol Global security.